A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Objective
The purpose of the Kilimanjaro study is to compare the investigational drug in various dosages, when combined with other approved treatments for multiple myeloma, to determine if anti-tumor activity seen with these medications is enhanced with Etentamig. In the Kilimanjaro study, participants will receive Etentamig + pomalidomide-dexamethasone. Study participants will be followed closely with clinic visits and tests.
Study Arms
The Valley Hospital is participating in Arm E (Etentamig with Pomalidomide and Dexamethasone). Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Pomalidomide and Dexamethasone, after 1-3 prior lines of therapy.
Eligibility
- Eastern Cooperative Oncology Group (ECOG) performance of <= 2.
- Must have confirmed diagnosis of Relapsed/Refractory (R/R) Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria.
- Must have measurable disease as determined by central lab as outlined in the protocol.
- Must be naïve to treatment with Etentamig.
- Must have never received BCMA-targeted therapy. Participants who have received targeted therapy against non-BCMA targets will not be excluded.
- Arm E: Participant has received 1-3 prior lines of MM treatment.
NCT ID
NCT05259839
